Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alan Matsumoto, MD
University of Virginia School of Medicine
Principal Investigator - Christopher J. Cooper, MD
University of Toledo
Principal Investigator - David Cohen, MD
Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO
Principal Investigator - Lance D Dworkin, MD
Rhode Island Hospital
Study Chair - Michael Steffes, MD
University of Minnesota
Principal Investigator - Timothy P Murphy, MD
Rhode Island Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Toledo
Toledo, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2004
- Primary completion
- 30 Sept 2013
- Completion
- 30 Sept 2013
- Last update posted
- 5 Oct 2015
- Registered enrollment
- 947
- Registry id
- NCT00081731
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.